Question

write a brief about teva pharmaceuticals . also write about its size , type, structure, operation , etc

Answer 1

Teva Pharmaceutical Industries is simply one of the world’s biggest makers of generic drugs. In Israel, it is the corporate version of a national celebrity.
Teva Pharmaceutical Industries Ltd also known as Teva Pharmaceuticals, it was Founded 1901 (119 years ago) and it was
Founded by Gunther Friedlander.
This is a multinational pharmaceutical company with dual headquarters in Petah Tikva, Israel (global) and Parsippany, New Jersey, U.S. (commercial). It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals.( A full list of products is available from www.tevagenerics.com.)It is the largest generic drug manufacturer in the world and one of the 15 largest pharmaceutical companies worldwide. The industry keep available facilities in Israel, North America, Europe, Australia, and South America. Teva shares are listed on the Tel Aviv Stock Exchange. The company is a member of the Pharmaceutical Research and Manufacturers of America .
Teva is pronounced TEH-VAH, with a soft "e." Teva is the Hebrew word for nature.

Noteworthy points about Teva Pharmaceutical Industries

Type:Public company

Traded as TASE: TEVA
NYSE: TEVA

ISINIL0006290147

ElsteinHeadquarters:Petah Tikva
Israel Parsippany, New Jersey U.S. (commercial)

, Subsidiaries: Actavis, Pliva, Teva Canada, Cephalon, Inc., Merckle GmbH, Anda, and more

Key people:Kare Schultz (president and​ CEO),Sol Barer (chairman) and
Mike McClellan (chief​ financial officer)

Products: Pharmaceuticals
Revenue US$18.9 billion (2018)

Number of employees:
42,535 (2018)

Website : www.tevapharm.com

The first homegrown, global success story and one of Israel’s largest employers, Teva is both a source of pride and a symbol of the country’s financial ambitions. Its place in the Israeli public’s imagination is similar to the one General Motors, in its heyday, occupied in America — but in a nation with a population about the size of New York City’s. The company’s shares are owned by so many pension funds that it is known informally as the people’s stock.
Today, many of those people are furious. Management missteps and tectonic shifts in the pharmaceutical business have battered Teva, which faces declining prices for generic drugs and the loss of a patent on a major branded drug. More than $20 billion has been shorn from the company’s market capitalization since 2017 began, cutting Teva’s value roughly in half.
Teva holds patents on multiple drugs, including: Copaxone, a specialty drug for the treatment of multiple sclerosis, now the world's best selling MS drug, and Azilect sold as Agilect in some countries for treatment of Parkinson's disease. By July 2015 Copaxone held a 31.2 percent shares of total MS prescriptions in the United States.Teva's new 40 mg version of Copaxone taken three times a week accounted for 68.5 percent of total Copaxone prescriptions in the United States.Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue.Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.
Teva Pharmaceutical Industries' November 2017 restructuring plan was necessary to cut costs by $3 billion by the end of 2019 due to a dramatic drop in revenues, stated CEO Kare Schultz in a press conference .Otherwise, the company would have gone bankrupt, he said.
Teva turnaround still coming after the stock's 70% loss in the past five years? Teva Pharmaceuticals one of the world's largest drug manufacturers, is still on track to recover from its trough year" in 2020, according to CEO Kare Schultz.

New organizational structure:
Teva Pharmaceutical has undertaken a number of acquisitions over the last several years, which led to multiple business functions with complicated structures. In order to optimize its operations and enable strategic alignment, Teva believes it is imperative to realign its business.

Teva now operates as one commercial organization in three regions: North America, Europe, and Growth Markets. Previously, the company operated through two global groups for specialty and generic medicines. Teva said some of the global units will be made redundant during the organizational optimization implementation. Two global R&D (research and development) divisions for generic and specialty medicines will be combined into one group.
The company has also established a new Marketing & Portfolio function. It will take care of the efficient interface between various geographic regions, R&D, and its operations throughout all stages of a product’s life cycle. The function will also be responsible for portfolio optimization of generic and specialty portfolios.
The VanEck Vectors Pharmaceutical ETF (PPH) is one of the major ETFs that could see a movement in prices with a turnaround in Teva’s business performance and related events. TEVA makes up 6% of PPH’s total portfolio.
As you have mentioned in your question a brief explanation...i tried my best to answer your question as brief hope you will like...if you need more explanation feel free to comment ...thank you